Philip R. Schauer, MD, Shares His Thoughts on the Necessary Direction of Accountable Care Organizations
Philip R. Schauer, MD, the director of the Bariatric and Metabolic Institute (BMI) at the Cleveland Clinic in Ohio contends that accountable care organizations (ACOs) need to recognize obesity as a legitimate disease that is the basis for many other serious conditions. He emphasizes that obesity certainly requires treatment, and surgery is an appropriate intervention for certain patients.
This video was taken at the American Diabetes Associations 73rd Scientific Sessions in Chicago, IL.
Two recent policy announcements, one from Medicare and another from the US Preventive Services Task Force, signal a shift toward understanding that America’s battle with obesity and diabetes is not only a medical but also a behavioral health problem, and must be treated as such.
Yesterday’s announcement that Pennsylvania will become the 27th state to expand Medicaid under the Affordable Care Act was closely watched in both healthcare and political circles, for it shows further accommodation to both local health needs and political considerations. Will Pennsylvania’s deal with the Centers for Medicare and Medicaid Services be the last, coming after Arkansas and Iowa? Or is it a sign that Medicaid, which has always combined federal mandates with some local flavor, will continue to shift with the political winds in the states?
The recommendation, based on a review conducted by KPRA EPC, identified significant changes in metabolic parameters like glucose, blood pressure, and LDL, following counseling, among individuals with cardiovascular risk factors.
The American Journal of Managed Care’s ACO Coalition, now at 100 members, gives healthcare leaders a way to share ideas for improving population health. A recent Web-based exchange involving Mount Sinai ACO’s diabetes strategy showed how the initiative is working to spread good ideas across the country.
The test, the first-ever to distinguish the type 1 form of diabetes, could detect the ZnT8 autoantibody in 65 percent of the samples from patients with diagnosed type 1 diabetes and gave false positive results in less than two percent of the samples from patients diagnosed with other disease.